Flagstar Bank NA vs GeneDx Holdings Corp — how do they compare? Flagstar Bank NA trades at $15.36 (market cap $6.26B), while GeneDx Holdings Corp trades at $64.42 (market cap $1.96B). The key difference: Flagstar Bank NA is far larger — about 3.2× GeneDx Holdings Corp's market cap, and Flagstar Bank NA pays a 0.27% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| FLG | WGS | |
|---|---|---|
Market Cap | $6.26B | $1.96B |
Sector | Financials | Technology |
52-Week High | $15.28 | $167.51 |
52-Week Low | $10.72 | $34.51 |
Dividend Yield | 0.27% | — |
Enterprise Value | — | $1.96B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx Holdings Corp. (WGS) trades at $65.785, up 5.37% today, but faces a bearish technical signal with the stock near resistance at $65. The company shows mixed fundamentals with strong revenue growth to $427.54M in 2025 but a net loss of -$21.02M, while analyst consensus remains bullish with a $75.40 price target. Recent news highlights multiple class-action lawsuits alleging securities fraud tied to a 49% stock decline and acquisition underperformance, creating significant investor uncertainty.
The outlook is highly conflicted: strong analyst buy ratings and recent earnings beats contrast with deepening losses, negative cash flow projections for 2026, and legal overhangs. Key risks include litigation outcomes, profitability challenges, and execution missteps, but the stock offers potential upside if the company can stabilize margins and resolve legal issues amid high institutional skepticism.
Trailing returns across standard periods
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →